What is the history of GEMZAR in treating first-line pancreatic cancer?
GEMZAR was first studied in clinical trials in the United States in the early ’90s, and was approved by the Food and Drug Administration in 1996 as a single agent for the 1st-line treatment of pancreatic cancer. GEMZAR has been a leader in the treatment of pancreatic cancer for more than a decade.